Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.

ABSTRACT:

Background

Dupilumab, targeting the interleukin-4α receptor and inhibiting the action of interleukin-4 and interleukin-13, was recently approved for treatment of moderate to severe atopic dermatitis. There is limited data on long-term effects and safety among patients with severe atopic dermatitis treated with dupilumab. Weight gain was observed among patients treated with dupilumab in our clinic. The aim was to describe weight change in a cohort study of patients with severe atopic dermatitis treated with dupilumab from baseline to follow-up after 12 months, and to analyze if weight change was associated with effect of treatment, reported appetite, and/or disturbed night sleep due to itching.

Methods

All patients with atopic dermatitis receiving systemic treatment at the Un

SUBMITTER: Johansson EK 

PROVIDER: S-EPMC7510313 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature